新生血管性年龄相关性黄斑变性玻璃体内抗血管内皮生长因子治疗后视网膜色素上皮撕裂的发生率及长期视力结局
回顾性分析800只连续初治新生血管性年龄相关性黄斑变性眼,分别接受阿柏西普(500眼)或雷珠单抗(300眼)治疗,随访34.0±9.1个月。阿柏西普组视网膜色素上皮撕裂发生率为3.2%,雷珠单抗组为2.3%(P=0.52)。29只发生撕裂眼平均随访30.76个月,视力从基线20/100下降至末次随访20/200,注射次数与最终视力正相关。
要点
- 阿柏西普组视网膜色素上皮撕裂发生率为3.2%,雷珠单抗组为2.3%(P=0.52)。
- 29只撕裂眼基线视力20/100,末次随访降至20/200。
- 抗血管内皮生长因子注射次数与最终视力正相关,支持继续治疗。
核心结论
- 阿柏西普注射后视网膜色素上皮撕裂发生率低,与雷珠单抗相似。
- 接受抗血管内皮生长因子治疗次数与视力结局的相关性支持继续抗血管内皮生长因子治疗的必要性。
研究设计与样本
- 回顾性分析连续初治新生血管性年龄相关性黄斑变性患者的临床病历、频域光学相干断层扫描和眼底荧光血管造影影像。
- 共纳入800只连续眼,其中300只接受雷珠单抗治疗,500只接受阿柏西普治疗,随访34.0±9.1个月。
主要发现
- 阿柏西普组视网膜色素上皮撕裂发生率为3.2%,雷珠单抗组为2.3%(P=0.52)。
- 29只发生视网膜色素上皮撕裂的眼平均随访30.76个月,基线视力为20/100(早期治疗糖尿病视网膜病变研究视力表50.7±19.3个字母),末次随访视力为20/200(早期治疗糖尿病视网膜病变研究视力表36.1±26.1个字母)。
- 平均注射次数在12个月时为7.3次,在研究结束时为13.9±8.1次。
- 注射次数与最终视力结局呈正相关。
临床怎么用
- 原文结论指出,抗血管内皮生长因子治疗次数与视力结局的相关性支持继续抗血管内皮生长因子治疗的必要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the incidence of retinal pigment epithelium tears in eyes treated with aflibercept for neovascular age-related macular degeneration and compare it with ranibizumab, and to describe long-term visual outcomes of retinal pigment epithelium tears after intensive anti-vascular endothelial growth factor treatment. METHODS: Retrospective analysis of clinical charts, spectral domain optical coherence tomography and fundus fluorescein angiography imaging of consecutive naive patients treated with intravitreal aflibercept or ranibizumab for neovascular age-related macular degeneration. RESULTS: Eight hundred consecutive eyes were included in the study (300 treated with ranibizumab and 500 with aflibercept) with 34.0 ± 9.1 months of follow-up. The incidence of tears in the aflibercept group was 3.2% and 2.3% after ranibizumab (P = 0.52). Twenty-nine eyes with retinal pigment epithelium tears were followed for a mean of 30.76 months. Visual acuity at baseline was 20/100 (50.7 ± 19.3 Early Treatment Diabetic Retinopathy Study letters) and 20/200 (36.1 ± 26.1 Early Treatment Diabetic Retinopathy Study letters) at the end of follow-up. The mean number of injection was 7.3 at 12 months and 13.9 ± 8.1 at the end of the study. The number of injections positively correlated with the final visual outcome. CONCLUSION: There was a low rate of retinal pigment epithelium tears after aflibercept injections, similar to ranibizumab. The correlation between the number of anti-vascular endothelial growth factors received and visual outcomes supports the need for continuing anti-vascular endothelial growth factor therapy.
引用
- Vazquez-Alfageme C, Nicholson L, Hamilton RD, et al. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2019. PMID: 29324593. doi:10.1097/IAE.0000000000002029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。